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CHAPTER I 
 
INTRODUCTION 
 
The mammalian pancreas has three main cell types: exocrine acini, pancreatic 
ducts, and endocrine islets.  Pancreatic β-cells comprise approximately 80% of the 
pancreatic islet in rodents.  The other cell types in the islet are glucagon-producing alpha 
cells, somatostatin-producing delta cells, pancreatic polypeptide-producing PP cells, and 
ghrelin-producing epsilon cells (Prado et al, 2004).  Although the islets only represent a 
small portion of the volume of the pancreas, they are highly vascularized and receive a 
large portion (6-20%) of the total pancreatic blood flow (Lifson, N, 1980 and Lifson, N, 
1985). The molecular mechanisms responsible for the vascularization of islets is the 
focus of this document and this will be discussed after a review of diabetes and glucose 
homeostasis. 
 
Diabetes Mellitus and Impact on Health 
Diabetes mellitus is a complex disease; it is a group of metabolic disorders 
wherein the cells of the body do not properly uptake/absorb and metabolize 
carbohydrates, fats, and amino acids (Thai,1993).  High blood glucose levels 
(hyperglycemia) is a diagnostic characteristic of diabetes mellitus, and eventually can 
cause damage to the retina, kidney, nerves, heart, and blood vessels.  There are four 
general categories of diabetes mellitus:  type 1, type 2, “other specific types”, and 
gestational diabetes (ADA, 2009).  
In type 1 diabetes the dysregulation of glucose homeostasis results from an 
autoimmune attack against the insulin-secreting pancreatic β-cells (ADA, 2009; Mathis, 
2001), usually leading to absolute insulin deficiency.  The majority of the persons with 
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type 1 diabetes mellitus develop the disease before the age of twenty-five, with an equal 
incidence in both males and females.   
Type 2 diabetes mellitus is characterized by insulin resistance in peripheral 
tissues and an insulin secretory defect of the β-cells (Costa, 2002).  This is the most 
common form of diabetes mellitus (90%) and is highly associated with genetics, obesity, 
inactivity, and older age.  In type 2 diabetes, insulin resistance and hyperinsulinemia 
eventually lead to impaired glucose tolerance.  Current thinking postulates that defective, 
“over-worked” β-cells eventually become exhausted, which further impairs insulin 
secretion, fuels the glucose intolerance, and leads to hyperglycemia (Costa, 2002).  The 
etiology of type 2 diabetes is multi-factorial and probably genetically based, but it also 
has strong behavioral, nutritional, and environmental components.   
Other types of diabetes mellitus are less common and are grouped together in a 
class called “other specific types” (ADA, 2009).  This group includes persons with 
genetic defects of β-cell function (formerly called MODY or maturity-onset diabetes in 
youth) or with defects of insulin action (ADA, 2009).  Persons with diseases of the 
exocrine pancreas, such as pancreatitis or cystic fibrosis, and persons with pancreatic 
dysfunction caused by drugs, chemicals or infections are also included in this category 
of diabetes (ADA, 2009).   
Gestational diabetes mellitus refers to women who develop diabetes mellitus 
during pregnancy.  Most women with gestational diabetes have normal glucose 
homeostasis during the first half of the pregnancy but have relative insulin deficiency in 
response to the insulin resistance of pregnancy and this leads to hyperglycemia during 
the last half of the pregnancy.  The hyperglycemia resolves in most women after 
delivery, but places them at increased risk of developing type 2 diabetes later in life 
(Daneman, 2006).   
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The significant morbidity and mortality of both type 1 and type 2 diabetes mellitus results 
predominantly from its complications, retinopathy, neuropathy, and nephropathy.  
Diabetes is a leading cause of blindness, renal failure, amputations, strokes, and 
cardiovascular events (Devendra, 2004; Mathis, 2001). Hyperglycemia and dyslipidemia 
are metabolic abnormalities of diabetes and lead to widespread cellular damage 
(Devendra, D. 2004).  
   
Current Therapies for Type 1 Diabetes 
Current management of type 1 diabetes involves daily blood sugar testing, insulin 
replacement, and careful meal planning. Insulin replacement is by either subcutaneous 
injection or subcutaneous infusion of insulin by an insulin pump.  There have been 
significant advances in the options/approaches available to assist patients in controlling 
and monitoring their blood glucose levels.  The current options include a repertoire of 
‘designer’ insulins with varying rates of pharmokinetics and programmable insulin pumps 
with a selection of delivery patterns and insulin-dosing algorithms (Powers, 2008).  
However, all current insulin replacement methods are imperfect and many patients have 
treatment-related hypoglycemia and develop diabetes-related complications in the long 
term.  Precisely matching insulin need and insulin delivery is one of the major limitations 
with current therapies.  Another therapeutic option is insulin replacement by 
transplantation of insulin-producing cells (cell-replacement therapy) (Robertson. 2004).  
Ideally, this therapy would mimic the biologically based glucose-sensing mechanism 
tightly coupled to insulin exocytosis, like that in the β-cell.  One such approach is islet 
transplantation (Fig.1), and this is a potentially effective therapy for insulin-deficient 
diabetes (Shapiro, 2000; Ryan, 2001; Robertson. 2004) (reviewed in Fig.1).  In this 
procedure, islets are isolated from the pancreas of a cadaver donor by intraductal 
delivery of the enzyme collagenase to the pancreas (Lakey, 1999). The collagenase 
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solution is slowly warmed to 35°C, transferred to a dissociation chamber and 
mechanically dissociated.  The selective islet cleavage is achieved by the use of highly 
purified collagenase/thermolysin blend such as Liberase HI (Roche, Indianapolis, IN); 
the islets are separated by gentle enzymatic and mechanical dissociation.  Ficoll 
gradients are used to purify the islets from the crude cellular sample (Sutton, 1984; 
reviewed by Fontaine, 2003).  For the transplant procedure, the surgeon uses ultrasound 
to guide placement of a small plastic catheter through the upper abdomen and into the 
portal vein (Rossini, 1999). The islets are then injected through the catheter into the 
liver.  Unfortunately, though the initial reports for islet transplants were promising, the 
long-term results have been disappointing since most of the patients must resume 
insulin injections within 3-5 years (Robertson, 2004, NEJM).  
 
Challenges for Islet Transplantation 
Several substantial challenges must be overcome before islet transplantation can 
be considered for widespread application.  One issue is the limited supply of suitable 
islets for transplant; there is an insufficient number of pancreatic donors compared with 
the number of type 1 diabetics (Robertson, 2004; Lakey et al, 2003; Ricordi and Strom, 
2004).  Another issue is that patients need to be on potent immunosuppressive 
medications to prevent rejection of the transplanted islets.  These medications weaken 
the immune system and increase the risk of infections.   
Another major challenge for islet transplantation is that the current duration of the 
islet allograft function is inadequate.  Several factors may impact the viability of 
transplanted islets and the success of islet transplantations, these include: (a) isolation 
procedure for the islets (Lakey JTR, 1999), (b) islet culture conditions (Gaber, 
2001;Fraga, 1998), and (c) the islet vascular supply during culture and after 
transplantation (Menger, 1998; Parr, 1980).  
  5 
One major issue affecting the function and survival of the islet allograft is that 
revascularization of islets after transplantation is required for successful engraftment 
(Carlsson, 2002; Davalli, 1996; Jansson, 1994).  However, the islet isolation process 
disrupts the vasculature of islets, resulting in a lack of blood supply to the islet graft in 
the first few days following the transplantation thus leading to hypoxia and death of islet 
cells (Mattsson, 2002; Davalii, 1996; Vajkoczy, 1995). Thus, immediately after 
transplantation, the pancreatic islets are supplied with oxygen and nutrients solely by 
diffusion from surrounding tissues. Therefore, the speed and the degree of 
revascularization of transplanted islets may be a major determinant of the survival and 
function of transplanted islets. Although the revascularization process is initiated 
immediately, it is generally thought to require 2-3 weeks post-transplantation before it is 
complete (Brissova, 2004; Mattsson, 2002; Menger, 1989; Sandberg, 1995). Even after 
revascularization is complete, oxygen tension and blood flow are reduced in islet grafts, 
independent of the site of transplantation (Carlsson, 2001).  The endothelium lining the 
newly formed blood vessels within islet grafts has been shown to be of both host and 
donor origin (Brissova, 2004; Schneider, 2000; Vajkoczy, 1995).  This revascularization 
process is thought to be mediated by angiogenesis, and is most likely mediated by 
intraislet and/or localized release of angiogenic factors.  
  
Pancreatic Islet Vascularization 
Pancreatic islets are highly vascularized mini-organs. In addition to islets being 
more densely vascularized than the surrounding acinar tissue, the morphology of islet 
vasculature is distinctly different from that of the surrounding exocrine pancreas. Islet 
vessels are thicker and more torturous than the vessels of the acinar tissue (Brissova, 
2006; Brunicardi, 1996).  Additionally, the endothelial cells of islet vessels are 
fenestrated (Brissova, 2006, Brunicardi, 1996).  Vascular fenestrations, an important 
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structural component for vascular permeability, are specialized plasma membrane 
microdomains in endothelial cells that appear as circular discontinuities of ~60 nm in 
diameter (Palade, 1979; Esser , 1998; Roberts, 1995; Brissova, 2006).  Islets also have 
higher pO2 (31-37 mmHg) than the exocrine pancreas (20-23 mmHg) (Carlsson, 1998; 
Carlsson, 2000, Carlsson, 2001).  
Increasing evidence supports the concept that the intra-islet vascular network is 
important for islet health and islet function.  A better understanding of molecular 
mechanisms underlying the development and maintenance of islet vasculature are of 
particular interest because of the benefits it could have on islet transplantation. 
 
Angiogenesis and Vasculogenesis 
Two different processes are involved in embryonic and extraembryonic blood 
vessel formation: 1) vasculogenesis, the de novo differentiation of endothelial cells from 
mesoderm and the organization of endothelial progenitors into a primitive vascular 
plexus; and 2) angiogenesis, the budding and branching of vessels from pre-existing 
vascular beds (Breier, 2000; Risau, 1995; Risau, 1997). Both these processes occur 
during organ development and differentiation in the embryo (Breier, 2000); angiogenesis 
is the primary mechanism by which new vessels form in the adult organism. In islets, 
angiogenesis is critical for normal islet formation during embryonic and early postnatal 
development (Ballian, 2007, Johansson, 2006, Brissova, 2006).  In the adult, 
angiogenesis is also required for tumor growth, wound healing, reproductive functions, 
and neoplasia (Johansson, M 2006, reviewed in Veikkola, 2000 and Ferrara, 2004; 
Folkman J, 1995).  Revascularization of the islet graft tissue into the donor tissue is 
thought to be mediated by angiogenesis (Jones, 2001). 
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Role of VEGF-A in Angiogenesis and Vasculogenesis 
Vascular endothelial growth factor-A (VEGF-A), is a critical angiogenic factor in 
vascular development, ischemia-induced angiogenesis, and tumor-related angiogenesis 
(reviewed by Ferrara, 2003; Folkman, 1987).  VEGF-A is the founder member of a family 
of growth factors, including VEGF-A, B, C, D, E, and placental growth factor (reviewed 
by Ferrara, 2003).  VEGF-A induces endothelial proliferation, promotes cellular 
migration, and inhibits apoptosis (reviewed by Ferrara, 2003).  While the other members 
of the family, VEGF-B, VEGF-C, and VEGF-D, have roles in selective areas, VEGF-A is  
thought to be the predominant member of the VEGF family (Ferrara, 2003), and is the 
subject of my thesis.  It is known that VEGF-A is crucial for embryonic development, as 
targeted inactivation of even a single VEGF-A allele results in embryonic lethality 
(Ferrara, 1996; Carmeliet, 1996).  Studies have shown that VEGF-A is critical during 
early stages of vascular development, and is required for survival in early postnatal life 
when the endothelium is still proliferating (Gerber, 1999). VEGF-A has also been shown 
to exert a pivotal role in angiogenesis under physiological and pathological conditions 
(Ferrara, 2003; Shibuya, 2001).  Additionally, VEGF-A has been widely studied in 
vascular disease, ischemic injuries, and in other transplanted areas (Byun 2001, Kim 
2004, Lee 2004), and we postulate that it plays an important role in the revascularization 
of islets after transplantation. 
The VEGF proteins mediate angiogenic signals to the vascular endothelium by 
binding to high affinity receptor tyrosine kinases (RTKs), termed VEGFR-1 (flt-1), 
VEGFR-2 (flk-1), and VEGFR-3 (FLT-4) (Neufeld, 1999; Ferrara, 2003).  All three 
receptors are expressed on endothelial cells and a limited subset of other cell types such 
as neurons (Neufeld, 1999; Lee, 1996; Ferrara, 2003).  In adults, VEGFR-1 and VEGFR-
2 are expressed primarily in the blood vessel endothelium, whereas VEGFR-3 is 
restricted largely to the lymphatic endothelium (Neufeld, 1999, Ferrara, 2003). The 
  8 
VEGFR-2 is thought to be the receptor that largely mediates the actions of VEGF-A as 
an endothelial cell mitogen and vascular permeability factor (Shibuya, M 2001).  
Targeted inactivation of either VEGF-A or VEGFR-2 interferes with angioblast 
differentiation and consequently with vasculogenesis (Shalaby, 1995; Carmeliet, 1996; 
Ferrara, 1997). The effects on vasculogenesis, large vessel formation, and capillary 
sprouting in both the VEGF-A knockout and VEGFR-2 knockout embryos are very 
similar (Carmeliet, 1996).  In both cases, embryos die between embryonic (E) day E8.5 
and E10 (Shalaby, 1995; Carmeliet, 1996).  The mouse knockout of VEGFR-1 also dies 
around E9 and displays unique vascular complications.  In contrast to VEGF-A and 
VEGFR-2 knockouts, mice lacking the VEGFR-1 gene display an increased number of 
endothelial progenitors and vascular disorganization (Fong, 1999, Fong 1995).   
 
Role of VEGF-A in Islet Vascularization 
Pancreatic islets express high levels of VEGF mRNA and proteins (Fig. 2), and 
the capillary network is about five times more dense than the capillary network of the 
surrounding exocrine cells (Brissova, 2006, Lammert, 2001, Christofori, 1995; Gannon, 
2002).  Additionally, VEGFR-2 is not expressed on pancreatic β-cells, but is expressed 
in the microvasculature of islets, exocrine tissues, and in the periductal capillary plexus 
(Brissova, 2006, Lammert, 2001).   Data from our lab has also shown that the level of 
VEGFR-2 is greater in islet vessels than in exocrine capillaries (Fig 2).  The localization 
and levels of VEGF-A in pancreatic islets suggests a paracrine mechanism of action by 
which VEGF-A secreted by islet cells modulates angiogenesis and vascular permeability 
in the capillary network of the islet-exocrine portal system (Fig 2).     
Inactivation of a floxed VEGF-A gene in mouse islets with different promoters 
driving Cre has resulted in the discovery that paracrine signaling from endocrine cells to 
the adjacent endothelial cells induces the formation of a dense network of fenestrated 
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capillaries in islets (Lammert, Cell 2003; Brissova, 2006).  Lammert and colleagues used 
the pdx1 (Pancreas-duodenum homeobox gene 1) promoter to delete VEGF-A in the 
mouse islets.  Studies in our lab inactivated VEGF-A in β-cells using RIP to drive Cre 
expression (Brissova, 2006).  Both studies showed that deletion of VEGF-A did not 
prevent or grossly disrupt endocrine pancreatic development.  Adult mice null for VEGF-
A in β-cells had normal pancreatic weight, insulin content, islet morphology, and islet 
architecture (Brissova, 2006). In the absence of VEGF-A, the development of islet 
capillaries was severely reduced (Brissova, 2006, Lammert 2003).  The few remaining 
capillaries found in the VEGF-A-deficient islets were poorly fenestrated and contain an 
unusual number of caveolae (Brissova, 2006, Lammert 2003).  Additionally, VEGF-A−/− 
islets appeared to develop adjacent to pancreatic blood vessels (Lammert, 2003). These 
studies also found that islet mass was not changed in the pancreas of −/− mice 
(Brissova, 2006), and that islets could reach a normal size, although the number of small 
islets appeared to be increased (Lammert, 2003).  
Interestingly, RIP-Cre; VEGFfl/fl  mice cleared glucose following intraperitioneal 
glucose at a slower rate than wild type mice (Brissova, 2006).  Plasma insulin levels, 
normalized for blood glucose after glucose administration, were also significantly lower 
in RIP-Cre; VEGFfl/fl mice as compared to wild type controls.  These results indicated that 
VEGF-A is important for the normal development of islet vasculature, and that islet 
function is affected by the abnormalities in islet microvasculature due to reduced VEGF-
A expression in β-cells.   
 
Limitations in Understanding of Islet Vascularization  
While much information has been gained from the RIP-Cre; VEGFfl/fl and Pdx1-
Cre; VEGFfl/fl models, these models have limitations. RIP-Cre is a well-characterized 
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transgenic mouse strain (Postic, 1999) in which Cre recombinase is under transcriptional 
control of the rat insulin promoter (RIP-Cre). In both the RIP-Cre; VEGFfl/fl and Pdx1-Cre; 
VEGFfl/fl mice, VEGF-A expression is reduced during embryogenesis (around E9.5-
E13.5).  Therefore, one was unable to discern the role of VEGF-A specifically in adult 
islet function and intra-islet vasculature maintenance.  Additionally, by reducing VEGF-A 
expression during islet development, there may be compensatory changes in other 
angiogenic factors in the islet, such as other members of the VEGF family or Ang-1.  A 
better understanding of the role of VEGF-A in the adult pancreas and mature islets 
would allow therapeutic manipulation of VEGF-A during islet isolation and perhaps post- 
islet transplantation.  
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Rationale for These Studies  
I hypothesize VEGF-A plays an important role in adult islets and is involved in 
maintaining the health and morphology of intra-islet vasculature. I predict that VEGF-A 
plays a key role in the maintenance of a fenestrated endothelial cell (EC) phenotype in 
adult islets, and that the preservation of the EC phenotype is needed for normal islet 
function.  Therefore to address the role that VEGF-A plays in adult islets, we 
conditionally and temporally inactivated VEGF-A expression in adult pancreatic islets.   
To accomplish this, we used an inducible version of the Cre/LoxP system, the CreERTM 
recombinase (Hayashi, 2002).  With this model, VEGF-A levels are unaltered during 
embryogenesis, so islets and islet vasculature develop normally.  This allowed us to 
examine the role of VEGF-A in adult islets.  
This document presents experimental data using two individual experimental 
approaches.  The first describes the characterization of two islet-cell-specific CreTM lines 
(RIP-CreER and Pdx1PB-CreER), and demonstrates the advantages and disadvantages of 
each strain.  In the second, we present results from studies on the effect(s) of down-
regulating VEGF-A in adult islets on islet function and islet vasculature. 
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CHAPTER  II 
 
CHARACTERIZATION OF INDUCIBLE CRE SYSTEM WITH R26R AND Z/AP 
REPORTER STRAINS 
 
 
 
Synopsis 
For the purpose of reducing VEGF-A expression in islets, we used islet-specific 
CreER transgenic lines: RIP-CreER and Pdx1PB-CreER.  The RIP fragment directs 
expression primarily in β-cells of the islet (Hanahan, D 1985).   Pdx1PB is a 1-kb 
fragment of the pancreatic duodenum homobox-1 promoter that is transcriptionally active 
in islet cells, but not in pancreatic exocrine cells, the stomach, or duodenum (Wu, 1997; 
Gannon, 2001).  The Pdx1PB-CreER transgene is expressed in all the endocrine cell types 
of the islet (Zhang, 2005).  
  Both transgenic strains were bred with Rosa26R (R26R) reporter mice (Soriano, 
1999) in order to determine the optimal method to administer tamoxifen and to test the 
recombination efficiency of the system.   By immunohistochemistry, tamoxifen-induced 
recombination in both the RIP-CreER and the Pdx1PB-CreER systems was observed.  
Unexpectedly, in the RIP-CreER bigenic mice, basal recombination was noted in the 
absence of tamoxifen administration. We also studied Z/AP reporter mice using RIP-
CreER.  We found that Cre-mediated recombination was partially dependent on the 
reporter gene used. 
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Introduction 
The Cre/loxP system is a tool that allows for tissue-specific inactivation of genes. 
This is especially useful for genes like VEGF-A where inactivation cannot be 
investigated in differentiated tissues because of embryonic lethality in mice with a 
conventional knock-out.  Recent advances in technology have modified this system so 
that it also allows for temporal inactivation of such genes (Sauer, 1998; Utomo, 1999).  
The CreERTM (CreER) recombinase is a fusion protein comprised of the catalytic domain 
of the Cre recombinase and the ligand-binding domain of a modified/mutated estrogen 
receptor (Hayashi, 2002).  This modification prevents the binding of endogenous 
estrogen at normal physiological concentrations, but renders the ER ligand-binding 
domain responsive to tamoxifen (Metzger, 1995).  The CreERTM protein is sequestered 
in the cytoplasm of the cell by heat shock protein 90 (Hsp90) (Metzger, 1995; 
Bockcamp, 2002).  Heat shock proteins are expressed by cells under conditions of 
stress, but they also function under normal physiological conditions (Hendrick and Hartl, 
1993).  Hsp90, named for the approximate molecular mass of the protein, is a molecular 
chaperone which functions include assisting in cell signaling, protein folding, and 
controlled switching of proteins between active and inactive conformational states  
(Hendrick and Hartl, 1993). Binding of tamoxifen disrupts this interaction with Hsp90, 
therefore allowing CreER to translocate to the nucleus and initiate loxP-mediated 
recombination (Fig. 3).   
R26R is a line of mice in which the β-gal reporter has been inserted into the 
Rosa26 locus and LacZ expression occurs only following the removal of an intervening 
stop sequence/segment by Cre recombinase (Soriano, 1999) (Fig.4).  This strain is 
commonly used for the monitoring the efficiency and pattern of Cre-mediated 
recombination.   
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Another reporter strain used to characterize Cre activity is Z/AP mice (Fig.4).  
This transgenic strain constitutively and ubiquitously expresses LacZ under the control of 
the CMV enhancer/chicken actin promoter (Lobe, 1999).  Expression is widespread, with 
a few exceptions (erythrocytes, chrondrocytes, and adiopocytes), and can be observed 
throughout all embryonic and adult stages.  When crossed with a Cre recombinase-
expressing strain, LacZ expression is replaced with human placental alkaline 
phosphatase (hPLAP) expression in tissues expressing Cre (Lobe, 1999).   Recent 
lineage tracing studies crossed the RIP-CreER line with Z/AP mice (Dor, 2004).  They 
reported that there was no Cre activity until the administration of the ligand, tamoxifen 
(Dor, 2004).   
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Methods and Materials 
 
Mouse models:  Mice heterozygous for the tissue specific inducible transgenic (RIP-
CreER or Pdx1PB-CreER) (Dor, 2004 and Zhang, 2005) were bred with R26R homozygotic 
mice (Soriano, 1999) or Z/AP mice (Lobe 1999).  Mice heterozygous for CreER and R26R 
or Z/AP represent experimental mice, while mice with only R26R or Z/AP serve as wild 
type controls.  Genotyping of mice was performed by PCR and Southern blot (Brissova, 
2006).  For PCR, mouse tail DNA was amplified in a thermal cycler using the following 
primers, 5’-CCA GGT TAC GGA TAT AGT TCA TG-3’, and 5’-TGC CAC GAC CAA GTG 
ACA GC -3’ (from Integrated DNA Technologies, Inc).   The size of the amplified product 
is approximately 213 bp.  For Southern blot analysis, tail DNA was digested using 
EcoRI, then run on a TBE agarose gel overnight.  Gels were then transferred onto a 
nitrocellulose membrane overnight.  Membranes were treated with 2% something SOC 
for 10 minutes.  The membrane was then dried in a vacuum oven for 1 hour at 65°C.  
The membrane was then washed with warm Erase Buffer for 15 minutes.  After which, 
the membranes were pre-hybridized between 4 hours to overnight at 65°C.  Membranes 
were then probed in hybridization buffer containing Cre cDNA labeled with 32P, and then 
exposed for autoradiography. 
 
Methods of Tamoxifen Injections: Tamoxifen is a selective estrogen receptor 
modulator.  It is part of a drug class termed anti-estrogens because it binds to the 
estrogen receptor and inhibits the binding of endogenous estrogen.  This property has 
made tamoxifen a widely used treatment for estrogen-sensitive breast cancer.  In 
humans, tamoxifen is typically taken orally in the form of a pill.  Due to its chemical 
structure, tamoxifen has a low solubility in water. Therefore, for the purpose of these 
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studies, tamoxifen was dissolved in either an aqueous solution containing ethanol or in 
corn oil.  For each route of tamoxifen administration, mice were given three doses of 
8mg of tamoxifen over the course of 5 days (every 48 hours).  Several methods of 
administering tamoxifen have been reported in the literature (Dor, 2004).  To determine 
which procedure was optimal for our studies, we compared the following three 
approaches:  
(1) Orally:  tamoxifen (Sigma) was suspended in aqueous solution of 3% ethanol 
and 0.5% methylcellulose at a concentration of 20mg/mL, and administered via 
oral gavage.    
(2) Intraperitoneally (IP): tamoxifen was dissolved in corn oil (Sigma) overnight at a 
concentration of 20mg/mL and stored at 4°C.  Intraperitoneal injections of 8mg 
were administered via sterile syringe into the visceral cavity.  
(3) Subcutaneously (SQ): tamoxifen was dissolved in corn oil overnight at a 
concentration of 20mg/mL and stored at 4°C.  Subcutaneous injections of 8mg 
were administered to the scapular region of each mouse.  
 
Immunocytochemistry and X-Gal Staining:  Pancreatic tissue was rinsed in ice-cold 
phosphate-buffered saline (PBS) and then fixed in 4.0% paraformaldehyde/0.1M sodium 
phosphate buffer for 1.5 h on ice.  After washing with PBS several times, pancreata were 
incubated with 30% sucrose and embedded in OCT compound (Tissue-Tek).   After 
fixation, 10 µm cryosections were prepared and assessed by either X-gal staining or 
immunostaining.  For immunohistochemistry, sections were fixed by immersion in 1% 
paraformaldehyde, washed with PBS three times, and then blocked in PBS with 5% 
normal donkey serum as previously described (Brissova, 2006). The primary and 
secondary antibodies were diluted in PBS containing 1% bovine serum albumin and 
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0.1% Triton-X-100.  The studies used the following: Guinea pig anti-human insulin IgG 
(1:1,000) from Linco Research, rabbit anti–β-galactosidase IgG (1:5,000) from ICN 
Pharmaceuticals, rabbit anti-Cre (1:5000) from Novagen.  β-galactosidase activity was 
also detected by postfixing with 0.2% glutaraldehyde/1%paraformaldehyde for 15 
minutes at room temperature.  The sections were then washed three times for 5 minutes 
with PBS, and permeabilized for 10 minutes at room temperature.  Sections were 
incubated with X-gal staining solution in a humidified chamber at 37°C, rinsed three 
times with PBS, and mounted with AquaPoly/Mount (Polysciences, Warrington, PA).  
Cells expressing hPLAP+ were identified by incubating slides with alkaline phosphatase 
substrate as described (Gu, 2002). 
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Results 
 
Subcutaneous administration of tamoxifen results in optimal recombination with 
less morbidity. 
  
 Seven days after the last administration of tamoxifen (oral, IP, SQ), the pancreas 
of RIP-CreER;R26R mice was removed, fixed, and stained.  By immunohistochemistry 
and X-gal staining, we found that oral administration of tamoxifen induced recombination 
in less then 10% of islet cells in bigenic mice (Cre transgene + R26R reporter insertion; 
data not shown).  Both intraperitoneal and subcutaneous injections of tamoxifen resulted 
in 75%-90% recombination in the islet cells of bigenic mice.  However, mice receiving 
intraperitoneal injections of tamoxifen or corn oil (n=4), lost weight and overall displayed 
diminished health, and in some cases died.  Three subcutaneous doses of 8mg 
tamoxifen induced sufficient recombination without affecting the health of the animal, 
and therefore was the dose and route of administration used for subsequent studies.   
   
Cre-Mediated Recombination Induced by Tamoxifen in RIP-CreER;R26R Mice 
 
The characterization studies of Cre-mediated recombination were performed on 
16 week RIP-CreER;R26R mice and R26R control mice.  To evaluate the efficiency of 
recombination in these mice, mice were injected with three doses of 8mg of tamoxifen 
and the pancreata was dissected one week after the last injection of tamoxifen.  As a 
control for any indirect effects of corn oil, a group of bigenic mice were injected three 
times with an equivalent volume of autoclaved corn oil. Sections of the pancreas of RIP-
CreER; R26R mice were stained with antibodies against β-gal and Cre (Fig 5).  
Costaining of sections with anti-insulin provided assessment of the β-cell population.  
Immunofluorescent imaging and MetaMorph analysis of Cre staining in bigenic mice 
demonstrated ~90% of β-cells per islet were positive for Cre (Fig. 5).  Non-β-cells of the 
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islet (those not expressing insulin) were Cre negative.  No β-gal or X-gal staining was 
detected in mice lacking the Cre transgene (data not shown).  At this dosage of 
tamoxifen, recombination was detected in 75-80% of the β-cells per islet.  However, to 
our surprise, a significant amount of recombination was observed in bigenic mice not 
treated with tamoxifen (Fig. 5).  Recombination in bigenic islets independent of 
tamoxifen was between 5-20% of β-cells per islet.  These results were unanticipated 
because previously published studies reported no recombination in RIP-CreER mice not 
treated with tamoxifen (Dor, 2004).   
A difference with our studies is that Dor & colleagues used the Z/AP reporter 
strain for genetic lineage tracing to investigate β-cell renewal and regeneration.  To 
investigate these differences, RIP-CreER mice were crossed with Z/AP reporter mice.  
RIP-CreER; Z/AP mice and Z/AP littermates were treated with tamoxifen or corn oil.  
hPLAP activity was assayed in pancreatic sections from RIP-CreER; Z/AP mice, treated 
and not treated with tamoxifen.  Recombination as indicated by hPLAP activity was 
noted only in islets of mice treated with tamoxifen (3X8mg).  No recombination was 
observed in the islets of bigenic mice not injected with tamoxifen (Fig. 6). These results 
indicate that the reporter gene construct in R26R mice and Z/AP mice explains the 
difference in the current work and work by Dor and colleagues. 
 
Efficient and Tamoxifen Dependent, Cre-Mediated Recombination in Pdx1PB-
CreER;R26R Mice 
 
Because the RIP-CreER system had spontaneous recombination in the absence 
of tamoxifen, we also evaluated Pdx1PB-CreER;R26R mice.  Analysis of Pdx1PB-
CreER;R26R pancreas sections by immunostaining indicated that Cre was expressed in a 
majority of the cells of the islet (data not shown).  Tamoxifen-induced recombination was 
observed in approximately ~80% of the endocrine cells per islet, as seen by 
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immunofluorescent staining for β-gal and X-gal staining (Fig. 7).  Little or no 
recombination was detected in the islets of bigenic mice not treated with tamoxifen (Fig 
7). 
 
Level of CreER Expression Differs in Pdx1PB-CreER and RIP-CreER lines 
To investigate possible reasons for the tamoxifen-independent recombination 
occurring in our RIP-CreER; R26R mice, we compared the level of Cre expression in 
each line by quantitating relative fluorescence intensity of Cre antibody staining using 
MetaMorph.  For this analysis, we stained the slides at the same time, under the same 
conditions, and then conducted image analysis them under identical settings. This 
analysis indicated that Cre expression in RIP-CreER;R26R was ~4X higher than Cre 
expression observed in Pdx1PB-CreER;R26R (Fig 8).  
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Discussion 
To characterize the tamoxifen-induced, Cre-mediated activity/efficiency of islet 
specific CreERTM lines, Pdx1PB-CreER and RIP-CreER, we crossed both transgenic lines 
with Rosa26R mice.  We found that both transgenes produced significant tamoxifen-
induced recombination in the islets of bigenic mice. We also found that Cre protein 
expression was substantially greater in RIP-CreER;R26R compared to Pdx1PB-
CreER;R26R.  Surprisingly, we saw a significant amount of Cre-mediated recombination 
in islets of RIP-CreER;R26R mice not treated with tamoxifen.  Conversely, little to no 
recombination was observed in the islets of Pdx1PBCreER mice not treated with 
tamoxifen.  
What is the likely explanation for the difference between Cre-mediated 
recombination directed by the RIP and Pdx1 promoters?  Cre recombinase-mediated 
excision is a stochastic event influenced by the level of the Cre enzyme and the 
availability of the loxP-flanked DNA sequence to the enzyme. In this system, Cre 
expression is determined by the characteristics of the promoters, RIP and Pdx1.  The 
insulin promoter is an extremely strong promoter and is the reason β-cells synthesize 
such high levels of insulin.  The RIP promoter has been widely used to engineer a large 
number of transgenic mice and a feature of these mice is the high level of protein 
expression in β-cells.  Conversely, Pdx1 is a transcription factor that plays a critical role 
in the pancreatic and islet development; inactivation of Pdx1 leads to pancreatic 
agenesis (Jonsson et al, 1994).  Pdx1 is also an important regulator of insulin gene 
transcription (Ohlsson et al, 1993).  As would be expected by the function of insulin (a 
secreted hormone) and the function of Pdx1 (transcription factor), the level of mRNA of 
the two genes is markedly different with the insulin mRNA being the most abundant 
mRNA in β-cells while pdx-1 mRNA is in low abundance.  Thus, the markedly different 
level of Cre protein in the two transgenic lines likely reflects the strength of the two 
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different promoters in β-cells. While other factors such as the insertion site of the 
transgene and the number of transgenes inserted may also influence transgene 
expression, it appears that the greater activity of the insulin promoter in β-cells is the 
most likely explanation for the greater level of Cre expression in RIP-CreER islets.  A 
limitation of the current study is that the absolute level of Cre protein was not quantified, 
but the relative expression by fluorescence intensity clearly indicates greater Cre 
expression in the RIP-CreER line.  Immunoblotting of protein extracts from the two mouse 
lines is needed to more precisely quantify the level of Cre expression.    
Why is there a difference between the R26R and Z/AP reporter lines when 
crossed with the same Cre transgene? With RIP-CreER producing a very high 
concentration of Cre protein, the probability of recombination at target loxP sites 
increases. We speculate that the RIP promoter may produce high levels of Cre protein 
that exceed the amount of Hsp90 in the cell, and thus, not all Cre molecules are 
sequestered in the cytoplasm.  Conversely, the Pdx1PB promoter, being less robust, 
would not drive such high expression thus all CreER protein would be bound by Hsp90. 
Therefore, in this instance the CreER protein would be retained in the cytoplasm.  
Another possible contributing factor is the availability of the targeted floxed allele to the 
Cre line varies between mouse lines or gene loci.  Therefore, if a Cre protein molecule 
does enter the nucleus independent of tamoxifen, the chances of recombination are 
dependent on the accessibility of the loxP site.  The mechanisms that influence the 
accessibility are incompletely defined but factors such as chromatin structure and 
packaging are likely involved.  Conversely, if an allele with a loxP site is less accessible 
to the Cre enzyme and the level of intranuclear Cre protein is low, then recombination is 
less likely to occur.  This likely explains the absence of basal Cre-recombination in RIP-
CreER;Z/AP mice, but basal recombination in RIP-CreER;R26R mice. 
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The amount of basal Cre-mediated recombination observed in RIP-CreER;R26R 
islets may be sufficient enough to impact studies aimed at temporally inactivating VEGF-
A in adult islets.  Given our interests in adult islets, we concluded that our VEGF-A 
inactivation experiments would use the Pdx1PB-CreER mice. 
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CHAPTER III 
 
INACTIVATION OF VEGF-A IN ADULT ISLETS 
 
Synopsis 
Vascular endothelial growth factor-A (VEGF-A) is a well known angiogenic factor 
in vascular development, ischemia-induced angiogenesis, and tumor-related 
angiogenesis.  Prior studies have reduced VEGF-A expression in mouse islets using Cre 
recombinase under the transcriptional control of rat insulin promoter (RIP-Cre) (Brissova, 
2006) and pancreas-duodenum homeobox gene-1 promoter (Pdx1) (Lammart, 2003).  
Both of these models demonstrated that VEGF-A is required for the development of 
normal endothelial cell morphology in pancreatic islets.  However, a limitation of these 
models is that VEGF-A is inactivated in islets during embryogenesis.  Thus, the role of 
VEGF-A in adult islets is still not known. Here we report on the temporal and conditional 
deletion of VEGF-A in pancreatic islets and the subsequent effects this reduction has on 
islet function and intra-islet vasculature.   
For these studies, we used Pdx1PB-CreER transgenic mice crossed with VEGFfl/fl 
mice (Pdx1PB-CreER; VEGFfl/fl). We show that in this model, administration of tamoxifen 
effectively reduces VEGF-A in pancreatic islets and reduced islet vascularization.  
Functional analysis of mice with islet inactivation of VEGF-A showed decreased glucose 
tolerance at one-week post tamoxifen injections.  However, this decreased glucose 
clearance was not observed in mice one-month after tamoxifen injections.    
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Methods and Materials 
 
Mouse models:  Mice heterozygous for the tissue-specific inducible transgenic (Pdx1PB-
CreER) (Zhang, 2005) were bred with homozygotic mice (mice with VEGF-A gene floxed 
on both alleles; VEGFfl/fl)(Gerber, 1999).  Subsequent littermates were bred to generate 
transgenic, homozygotic floxed mice (Pdx1PB-CreER; VEGFfl/fl) and non-transgenic, 
homozygotic floxed mice (VEGFfl/fl).   
 
Glucose tolerance testing:  Intraperitoneal glucose tolerance testing (2g/kg body wt) 
was performed on mice (13-18 wks of age) after a 14-16 hr fast (Brissova, 2006).  
Plasma glucose was measured in whole blood by use of a Roche Accu-check glucose 
meter. Blood glucose was measured before administration of glucose and at 15 mins, 30 
mins, 60 mins, 90 mins, and 120 mins after glucose injection.  
  
Tamoxifen injections: Tamoxifen was dissolved in corn oil overnight at a concentration 
of 20/mg/mL and stored at 4°C.  Three subcutaneous injections of 8/mg were 
administered as described in Chapter II.  
 
Tissue collection and histological assessment of pancreatic islets: 
Mice were infused with fluorescein isothiocynate conjugated tomato lectin (Lycopersicon 
Esculentum; 1mg/mL; Vector Laboratories, Burlingame, CA) via the jugular vein 
(Brissova, 2006).  This lectin binds specifically to endothelial cells.  Lectin was allowed to 
circulate for 7 minutes, the pancreas was then removed and fixed in 4% PFA/0.1M PBS 
for 1.5 hours on ice.  Afterward, tissues were washed several times with 10 mM PBS 
and then cryoprotected with 30% sucrose/0.1M PBS and embedded in OCT compound 
(Tissue-Tek). After fixation, 10 µm cryosections were stained with antibodies for insulin, 
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Cre and lectin were visualized and imaged by fluorescence microscope (MagnaFire 
Digital Camera, Optronics connected to an Olympus BX-41 fluorescence). Primary anti-
bodies used were: Guinea pig anti-human insulin IgG (1:1,000) from Linco Research and 
rabbit anti-Cre (1:5000) from Novagen. Antigens were visualized using secondary 
antibodies conjugated with Cy2, Cy3, and Cy5 fluorophors from Jackson 
ImmunoResearch Laboratories (West Grove, PA) at concentrations recommended by 
the manufacturer.  Primary and secondary antibodies were diluted in phosphate-buffered 
saline containing (PBS) 1% bovine serum albumin and 0.1% Triton-X-100.  The 
cryosections were blocked with 5% normal donkey serum (Jackson ImmunoResearch 
Laboratories) and then incubated with the primary antibodies overnight at 4°C.  
For evaluation of intra-islet vascular density, non-overlapping images of an entire 
pancreatic section were taken under the 20X objective to visualize the antibody and 
lectin binding.  Using MetaMorph v6.1 software (Universal Imagine, Downington, PA.), 
integrated morphometry of 10-20 islets per section (5-6 sections/mouse) was used to 
calculate islet area and the area of the islet vasculature.  To systematically quantify 
endocrine cell mass, 10 µm pancreatic sections spaced by 100µm from 3 different layers 
of the pancreatic tissue block (2 pancreata per genotype) were examined. 
 
Islet isolation and Enzyme-linked immunosorbent assay (ELISA):  Islets were 
isolated from Pdx1PB-CreER; VEGFfl/fl and wild type mice by dissection of the splenic 
portion of the pancreas followed by digestion with Collagenase P (Roche Molecular 
Biochemicals) (Brissova, 2006).  Groups of two pancreata were digested in 2 ml of 
collagenase/pancreas in Hanks buffered saline (GIBCO) for 6-9 mins at 37°C using a 
wrist-action shaker.  Islets were handpicked under microscopic guidance and separated 
from exocrine tissue by serial transfers/picks into clean dishes.  Islets (n=70 per well) 
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were cultured in 500ul of RPMI 1640 (11mM glucose) for 48 hours at 37°C.  Culture 
media and islets were collected at 48 hours.  Media and islets were centrifuged at 4°C at 
2000/rpm, then 450ul of media was collected into a separate eppendorf tube.  The islets 
were then washed four times with cold PBS, and then stored at -80°C.  VEGF-A levels 
were measured in the media by ELISA (R&D Systems).  
    
Radioimmunoassay (RIA):  Mouse plasma insulin was determined by a heterospecies-
specific RIA (Brissova, 2006) with guinea pig anti-rat insulin serum, rat insulin reference 
standard, normal guinea pig serum, goat anti-guinea pig gammaglobulin serum (Linco 
Research), and 125 I-human insulin (Diagnostic Products). The RIA has a sensitivity 
(ED90) of 7.5 pg of insulin/ml, which converts to 150 pg of insulin/ml when using 5 µl of 
mouse plasma/assay tube. 
 
Statistical analysis: To compare the outcomes in the different genotypes, we used 
unpaired t-test and one-way analysis of variance with Newman-Keuls multiple 
comparison.  The data were expressed as mean +SE.  
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Results 
 
Administration of Tamoxifen to Pdx1PB-CreER; VEGFfl/fl mice effectively reduces 
VEGF-A levels 
  
 To determine the efficiency of Cre-mediated recombination in pancreatic islets, 
VEGF-A protein secreted by isolated islets from tamoxifen-treated and control Pdx1PB-
CreER; VEGFfl/fl and VEGF fl/fl mice was quantified by ELISA.  Islets were isolated from 
Pdx1PB-CreER; VEGFfl/fl (n=4) and VEGFfl/fl (n=4) mice at the following time points: (A) 
pre-tamoxifen (B) 7 days after the last tamoxifen injection (C) 30 days after the last 
tamoxifen injection.  Isolated islets (70 islets per well, n=4) were cultured for 48 hours.  
Before tamoxifen treatment, VEGF-A secretion, by islets from Pdx1PB-CreER; VEGFfl/fl 
and VEGFfl/fl mice was similar, measuring ~2.5-3.0 pg/islet/48hrs (Fig 9).  Administration 
of tamoxifen reduced VEGF-A production ten-fold by Pdx1PB-CreER; VEGFfl/fl islets, 
measured at one week and 1 month after tamoxifen treatment (Fig. 9).  The reduction of 
VEGF-A secretion in Pdx1PB-CreER; VEGFfl/fl islets is comparable to that seen in isolated 
islets from RIP-Cre; VEGFfl/fl mice (Brissova, 2006).  VEGF-A expression was unaltered 
in VEGFfl/fl mice at 7 days and 30 days post tamoxifen (Fig. 9). 
 
Islet Vasculature is altered by reduced VEGF-A expression 
Based on prior data from RIP-Cre;VEGFfl/fl studies (Brissova, 2006; Lammert, 
2003), we knew that reduced VEGF-A production in islets, during embryogenesis, 
resulted in decreased vascular density and vessel area. To determine the impact of a 
reduction in VEGF-A on adult islets, we measured the same vascular parameters.  
Reduced VEGF-A expression in tamoxifen-treated Pdx1PB-CreER; VEGFfl/fl mice led to 
altered islet vasculature (Fig. 10).  Vessel density and area per vessel were similar in 
Pdx1PB-CreER; VEGFfl/fl and VEGFfl/fl islets pre-tamoxifen treatment (Fig.10 B and C).  
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Vasculature perimeters were unchanged in VEGFfl/fl islets at either one-week or one-
month after tamoxifen treatment (Fig.10 B and C).  There appeared to be a trend toward 
decreased density in Pdx1PB-CreER; VEGFfl/fl islets, as seen by lectin staining one week 
after tamoxifen treatment.  Vessel density of Pdx1PB-CreER; VEGFfl/fl islets was 
significantly reduced 30 days post tamoxifen treatment (Fig. 10B).  The area per vessel 
of Pdx1PB-CreER; VEGFfl/fl islets was significantly reduced at both 7 days and 30 days 
post tamoxifen treatment (Fig. 10C).     
 
Glucose tolerance in tamoxifen-treated mice 
To elucidate the relationship between VEGF-A, islet vasculature, and islet 
function, we subjected Pdx1PB-CreER;VEGFfl/fl  and VEGFfl/fl mice to intraperitoneal 
glucose tolerance tests at (A) pre-tamoxifen (B) 7 days after the last tamoxifen injection 
(C) 30 days after the last tamoxifen injection.  Glucose clearance was similar between 
Pdx1PBCreER; VEGFfl/fl and VEGFfl/fl groups pre-tamoxifen treatment (Fig. 11A).  The 
glucose clearance of VEGFfl/fl mice was unaltered by tamoxifen treatment (Fig. 11B). 
Tamoxifen-treated Pdx1PB-CreER; VEGFfl/fl mice had normal fasting blood glucose levels, 
but there was a slight, but significant delay in glucose clearance in Pdx1PB-CreER; 
VEGFfl/fl mice 7 days post tamoxifen treatment.  Interestingly, this delay in glucose 
clearance was not observed in Pdx1PB-CreER; VEGFfl/fl mice 30 days post tamoxifen 
treatment (Fig. 12).  We also monitored random non-fasting blood glucose of Pdx1PB-
CreER; VEGFfl/fl and VEGFfl/fl mice throughout the course of the experiment and these 
were normal (data not shown). 
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Discussion 
To determine the efficiency of VEGF-A inactivation in islets of Pdx1PB-
CreER;VEGFfl/fl, we measured VEGF-A protein produced by isolated islets harvested 
before and subsequent to tamoxifen injection. The level of VEGF-A expression in 
Pdx1PB-CreER;VEGFfl/fl  islets prior to treatment was similar to that of the VEGFfl/fl islets, 
indicating that Cre was properly being sequestered in the cytoplasm of this model. We 
observed a significant reduction in VEGF-A secretion by islets from Pdx1PB-
CreER;VEGFfl/fl  islets 7 days and 1 month post injection.  In contrast, there was no 
significant change in VEGF-A secretion from VEGFfl/fl islets at the same time points.   
Previous studies suggest that VEGF-A is a major regulator of islet vascularization 
and islet function (Brissova, 2006; Lammert, 2003).  In our study, we demonstrated that 
inactivation of VEGF-A in adult islets does effect intraislet vasculature.   Measurements 
of the vascular parameters of Pdx1PB-CreER;VEGFfl/fl islets showed a trend of decreased 
vessel density at one week and a significant reduction at one month. The area/vessel 
was reduced at 7 days and at 1 month.  This reduction in islet vascular parameters 
indicates that maintenance of islet vascularization is dependent on VEGF-A production 
by islet cells and that when VEGF-A levels are reduced, intra-islet vessels regress.  How 
this occurs requires further study into the fate of endothelial cells that line intra-islet 
vessels and extracellular matrix that comprises the capillary structure.  A possible 
hypothesis is that intra-islet endothelial cells undergo apoptosis and cell death without 
constant VEGF-A stimulation and that without endothelial cells the basement membrane 
of capillaries are not maintained.  The reduction in islet vessel area at 7 days suggests 
that the reduced vessel area precedes the loss of vascular structures quantified by 
measuring vessel density.  Previous studies suggest that blood vessel type-specific and 
tissue-specific characteristics of endothelial cells are under the control of their 
microenvironment (Lacorre, DA 2004).  Additional experiments using 3D reconstruction 
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of adult islet vasculature and electron microscopy of endothelial cells in our model would 
determine if the ultrastructure of the endothelial cells is acutely and/or chronically altered 
when VEGF-A expression is down-regulated. 
 This change in vascular density in Pdx1PB-CreER;VEGFfl/fl mice 7 days post 
injections coincided with a significant delay in glucose clearance.  However, a difference 
in glucose clearance was no longer observed one month after tamoxifen treatment.  This 
initial correlation between islet function and reduced vasculature and vessel area seen at 
7 days post tamoxifen treatment, is similar to what has been previously observed  in the 
RIP-Cre;VEGFfl/fl studies in our lab (Brissova, 2006), showing that even a 25% reduction 
in islet vessel density results in impaired islet function.  The impairment of glucose 
clearance at one week could be explained by: 1) the reduction in vessel size causing 
decreased flow into the VEGF-A mutant islets, this could result in a lower or delayed 
beta cell response, or 2) alterations in the ultrastructure of the islet endothelial cells 
could slow the delivery of insulin into the vascular system.   
 This apparent ‘recovery’ of islet function seen at 30 days post treatment could be 
explained by compensatory actions by other angiogenic factors known to be present in 
endocrine cells.  For example, the reduction in islet cell production of VEGF-A, could 
lead to an upregulation of an angiopoietin or an ephrin, or even another member of the 
VEGF family.  Quantitative and qualitative experiments would help to determine if the 
levels of other angiogenic factors are altered in response to a reduction of VEGF-A.  Or 
perhaps β-cells compensate for this reduced vessel density by changing their glucose 
sensitivity or efficiency of insulin secretion. These possibilities could be investigated by 
examining insulin in isolated islets, by quantifying β-cell gene expression of proteins 
involved in glucose-stimulated insulin secretion, and by examining β-cell ultrastructure 
by electron microscopy.   
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Summary and Conclusions 
 
Pancreatic islets are highly vascularized and receive a much greater blood flow 
than surrounding pancreatic exocrine tissue.  This is likely important in the rapid sensing 
of the blood glucose and secretion of insulin by the β-cell in response to a glucose 
ingestion. Earlier data from knockout studies of VEGF-A in islets provide evidence of the 
importance of this angiogenic factor during development for normal islet function and 
normal intra-islet vasculature.  This thesis focuses on the role of VEGF-A, a major 
determinant of islet vascularization, in adult islet vasculature and function.  This is not 
only a question of biologic interest, but may be relevant to both the pathogenesis and 
treatment of diabetes mellitus as discussed in Chapter 1.  In type 1 diabetes, islet 
transplantation is an emerging, but experimental, therapy. While this cell-based therapy 
has shown promising results, several factors prevent it from being widely adapted as a 
form of treatment (reviewed in Chapter 1).  The work in this thesis is relevant to one of 
those limitations: revascularization of transplanted islets. In type 2 diabetes, inadequate 
insulin secretion could result from abnormalities in islet vascularization.  Thus, we hope 
that the studies described in this thesis contribute to a greater understanding of the role 
of VEGF-A in adult islets and may also have implications for human disease. 
To investigate the role of VEGF-A in adult islets, we utilized an inducible Cre/loxP 
system.  We studied two different Cre transgenes that allowed us to temporally and 
spatially inactivate VEGF-A in pancreatic islets.  In Chapter 2, we describe our findings 
that both RIP-CreER and Pdx1PB-CreER lines efficiently direct islet cell-specific, Cre-
mediated recombination following tamoxifen administration.  Surprisingly, we found that 
RIP-CreER mice had small, but significant, amount of Cre-mediated recombination 
without tamoxifen administration in the R26R reporter line.  This was different from a 
prior report in the literature and prompted further investigation.  Interestingly, we found 
that the Cre-mediated recombination without tamoxifen administration did not occur 
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using a different reporter line, Z/AP (the reporter line used in the prior report).   We found 
that Cre expression was 4 times greater than RIP-CreER compared to Pdx1PB-CreER 
mice.  Our comparative studies of the various methods for administering tamoxifen 
demonstrated that oral or intraperitoneal was not optimal routes of administration - both 
for reasons of recombination efficiency and impact on the health of the animals.  Finally, 
we found that Cre-mediated recombination was efficiently and safely induced by 
subcutaneous administration of tamoxifen, with a high percentage of recombination 
accomplished with 3 doses of 8mg of tamoxifen. 
These results with two different Cre lines and two reporter lines indicate that both 
the promoter driving Cre expression and floxed allele are important variables to consider 
when using the Cre/LoxP systems.  Since the level of CreER expression will vary 
depending of the promoter and every CreER transgene will have a different insertion site, 
investigators must consider this in both the design and interpretation of experiments 
using a CreER transgene.  For example, if two promoters have a similar cell-specific 
expression pattern, but one is a highly expressed in that cell type and the other is 
expressed a lower level, then basal (non-tamoxifen-mediated) recombination may occur 
in one line but not in the other.  Likewise, every floxed allele will be different and the 
accessibility of the allele to the Cre enzyme may be an important variable.  In our studies 
using the highly active RIP promoter, the R26R allele appeared very sensitive to small 
amounts of Cre in the nucleus.  These findings suggest that if an investigator was using 
a “sensitive” or an “accessible” floxed allele, there might be some inactivation of the 
gene of interest without tamoxifen administration.  This low level inactivation could affect 
cell function if the level of expression of the gene of interest was critical and might not be 
easily detected.  We were concerned about such an effect on the floxed VEGF-A allele, 
especially since prior studies have suggested that islet vascularization is very sensitive 
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to the level of VEGF-A expression.  Thus, we used only Pdx1PB-CreER;VEGFfl/fl for 
subsequent studies.   
In the studies to investigate the role of VEGF-A in adult islet vascularization, we 
found that reduced VEGF-A expression in Pdx1PB-CreER;VEGFfl/fl islets decreased the 
vascular density and vessel area of islets (Chapter 3).  Consequently, this loss of VEGF-
A impaired glucose clearance when tested one-week post tamoxifen injection.  However, 
reduced VEGF-A expression had no significant effect on glucose clearance in Pdx1PB-
CreER;VEGFfl/fl mice when tested one-month post tamoxifen injection. In parallel, control 
experiments, tamoxifen administration did not alter VEGF-A expression, effect glucose 
tolerance, or reduce vasculature in VEGFfl/fl islets.  Additionally, VEGF-A expression in 
non-treated Pdx1PB-CreER;VEGFfl/fl islets was in the same range as VEGFfl/fl islets. 
Our results indicate that VEGF-A in adult islets also plays an important role in the 
maintenance of intra-islet vasculature. Intra-islet vasculature appears sensitive to 
changes levels of VEGF-A post development, suggesting plasticity in the morphology 
and architecture of islet vasculature.  The relationship between VEGF-A expression and 
islet function is still unclear and further work is needed. 
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Future Studies 
Work on this project is continuing in our laboratory and a number of scientific 
questions remain unanswered.  Potential studies or scientific questions include: 
• What are the long-term effects of VEGF-A inactivation in the adult islet?  Mice could 
be treated with tamoxifen and then followed for larger periods of time.  Insulin 
secretion by isolated islets and more sophisticated methods for assessing insulin 
secretion in vivo (pancreas perfusion or hyperglycemia clamping). 
• How would reduced levels of VEGF-A affect islets during transplantation? 
• Is there a compensation for the reduced VEGF-A level?  The reduction in VEGF-A 
could lead to an upregulation of an angiopoietin or an ephrin, or even another 
member of the VEGF family.  Quantitative and qualitative experiments would help to 
determine if the levels of other angiogenic factors are altered in response to a 
reduction of VEGF-A.  Or perhaps there is compensation of β-cells.  Can they alter 
their function and response to glucose? Can they secrete more insulin? One would 
measure insulin levels and in response to various secretagogues. 
• There are also several areas of potential future experiments related to the CreER 
system.  For example, a limitation of this work is that the level of Cre protein was 
not quantified (we assessed relative expression by fluorescence intensity).  
Immunoblotting of protein extracts for Cre from the two mouse lines is needed to 
more precisely quantify the relative amount of Cre protein in the two transgenic 
lines.  Likewise, one could also investigate the reasons that the two reporter mice 
differed in their susceptibility to Cre-mediated recombination.  Does this relate to 
epigenetic modifications, chromatin structure or methylation? 
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